Prot #CC-10004-BCT-002: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study, followed by an Active-Treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects with Active

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date1/26/151/26/21

    Funding

    • PPD Development (Prot #CC-10004-BCT-002)
    • Celgene Corporation (Prot #CC-10004-BCT-002)